 |
| Anno I | Numero 7 | Novembre 2016 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
| Collaborazione Corriere della Sera – AIOM |
Nuova Web-app |
|
Una web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del polmone è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica. Strumento interattivo in due versioni, per tablet/computer e smartphone, è il primo di una serie di 6 su altrettanti tipi di tumori per aiutare i cittadini a capire come si può prevenire e diagnosticare in tempo la malattia. |
| Leggi e scarica |
| Notizie dalla ricerca |
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer |
| Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non-small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing … |
| Continua a leggere |
| PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? |
| Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1 on immune cells and PD-L1 on cancer cells have been used to successfully treat non-small cell lung cancer (NSCLC), including some durable responses lasting years. Two drugs, nivolumab and pembrolizumab, are now FDA approved for use in certain patients who … |
| Continua a leggere |
| PD-1 axis inhibitors in EGFR and ALK Driven Lung Cancer: Lost cause? |
| Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immuno-therapeutics for advanced smoking associated non-small cell lung cancer. Their role in treating EGFR mutant and ALK rearranged lung cancer has yet to be determined … |
| Continua a leggere |
| Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future? |
| The goal of re-programming the host immune system to target malignancy with durable anti-tumour clinical responses has been speculated for decades. In the last decade such speculation has been transformed into reality with unprecedented and durable responses to immune checkpoint inhibitors seen in solid tumours. This mini-review considers the mechanism of action of immune modulating agents and the potential for combination with radiotherapy in the treatment of non-small cell lung … |
| Continua a leggere |
| Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data |
| Lung cancer is the leading world cause of cancer-related death, in both genders, and smoking is the main etiological factor. The discovery of immune checkpoints corroborates the hypothesis that ligands presented in tumors modulate the mechanisms of carcinogenesis and the immune activity of tumor microenvironment. Among the most studied coregulatory molecules, PD-1 (programmed cell death 1) and its ligand PD-L1 (programmed cell death 1 ligand 1) are noteworthy. The present study aims to … |
| Continua a leggere |
| Appuntamenti AIOM |
| Nuove Frontiere Diagnostico-Terapeutiche nelle Neoplasie Polmonari, Renali e nel Melanoma |
| Varese, 12 novembre 2016 |
| Lung Collection 2016. Costruiamo un algoritmo |
| Milano, 16 novembre 2016 |
| Master Class in Oncologia. Lung Cancer |
| Firenze, 17 – 18 novembre 2016 |
| Coniugare innovazione, sostenibilità e continuità di cura in oncologia: il ruolo delle reti regionali |
| Milano, 19 novembre 2016 Convegno Interregionale AIOM Lombardia, Liguria, Piemonte e Valle D'Aosta |
| Le reti oncologiche regionali: dal governo clinico alla definizione del PDTA |
| Firenze, 23 novembre 2016 |
| First International Congress Clinical Needs and Translational Research in Oncology |
| Reggio Emilia, 28 – 29 novembre 2016 |
| Novità nei Tumori Polmonari |
| Bolzano, 30 novembre 2016 |
| Immunotherapy Bridge 2016 |
| Napoli, 30 novembre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
Questo progetto è stato realizzato con il contributo di  |